The substantial safety improvement and trial amendment to a registrational path are significant catalysts. Monitor for additional Phase 1 data and End-of-Phase 1 FDA meeting in H2 2026, which could de-risk LYL273's regulatory pathway and support a pivotal trial start.
Price Chart
Executive Summary
Lyell Immunopharma announced updated safety data from its Phase 1 trial of LYL273 in metastatic colorectal cancer, showing GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% to 10%. The trial was amended to a Phase 1/2 design enabling a potential pivotal single-arm Phase 2 trial, with an End-of-Phase 1 FDA meeting and additional clinical data expected in H2 2026.
Key Facts
- GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% (without prophylaxis, N=9) to 10% (with prophylaxis, N=10).
- No Grade ≥3 CRS or ICANS observed in patients receiving GI prophylaxis.
- Maximum tolerated dose has not yet been determined; dose escalation continues.
- Phase 1 trial amended to Phase 1/2 design (CARABINER) enabling seamless expansion into a potential pivotal single-arm Phase 2 trial.
- New cohorts added: second-line cohort and combination with radiotherapy; up to 60 patients expected across new cohorts.
- End-of-Phase 1 FDA meeting and additional Phase 1 clinical data expected in H2 2026.
- LYL273 has FDA Fast Track designation for mCRC.
- Previously reported 50% overall response rate across Dose Levels 1 and 2 (data cutoff Oct 28, 2025) in 3L+ mCRC.
Financial Impact
No financial figures disclosed; early-stage clinical data with no revenue or deal value.
Risk Factors
- Maximum tolerated dose not yet determined; dose escalation could reveal unexpected toxicity.
- Phase 2 regulatory alignment with FDA is pending and not guaranteed.
- Small sample size (N=19) limits statistical reliability of safety and efficacy data.
- Solid tumor CAR-T remains a challenging field with high historical failure rates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307886 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.26 (−40.22%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.26 (−27.88%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.26 (−25.56%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.26 (−31.41%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.26 (−24.78%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.26 (−22.64%) |
Apr 24, 2026 23w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.26 (−59.06%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.26 (−61.16%) |
Apr 3, 2026 26w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.26 (−57.31%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.26 (−56.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access